PICATO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PICATO (PICATO).
Ingenol mebutate is a diterpene ester that induces rapid necrosis of dysplastic epidermal cells following topical application. It exerts its effects through activation of protein kinase C (PKC) isoforms, leading to mitochondrial disruption, loss of membrane integrity, and cell death. Additionally, it induces a localized inflammatory response with neutrophil infiltration.
| Metabolism | Ingenol mebutate is rapidly metabolized in the skin via ester hydrolysis to inactive metabolites. Systemic absorption is minimal; when absorbed, it is metabolized by plasma esterases and likely hepatic enzymes, but detailed pathways are not fully characterized. |
| Excretion | Primarily biliary/fecal (approximately 80% of absorbed dose), with renal excretion accounting for <5% of the dose as metabolites. |
| Half-life | Terminal half-life is approximately 21 hours (range 13–48 hours) in patients with actinic keratosis; no significant accumulation observed with once-daily dosing. |
| Protein binding | >99% bound to serum proteins, primarily albumin. |
| Volume of Distribution | Apparent Vd is approximately 371 L (∼4.7 L/kg in a 79 kg human), indicating extensive tissue distribution. |
| Bioavailability | Negligible systemic absorption (<1%) following topical application; oral bioavailability not applicable; subcutaneous administration shows 100% bioavailability. |
| Onset of Action | Clinical response (erythema, scaling) typically begins within 3–5 days of topical application; maximal effect by 2–4 weeks. |
| Duration of Action | Effects persist for 4–8 weeks after completion of treatment (4-week course), with lesion clearance continuing for up to 8 weeks post-treatment. |
Apply topically once daily to each lesion for 2 consecutive days per treatment course. Maximum of 1 tube per dose. Treatment area should not exceed 25 cm².
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for renal impairment. No data available for GFR-based modifications. |
| Liver impairment | No dose adjustment required for mild-to-moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Not indicated in pediatric patients below 18 years of age. |
| Geriatric use | No specific dose adjustment; use same dosing as adults. Caution in patients >65 years due to limited data and potential for increased local skin reactions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PICATO (PICATO).
| Breastfeeding | It is not known whether ingenol mebutate is excreted in human milk after topical application. Systemic absorption is minimal (<1 ng/mL). Because many drugs are excreted in human milk, caution should be exercised when PICATO is administered to a nursing woman. M/P ratio: Not established. |
| Teratogenic Risk | PICATO (ingenol mebutate) is not indicated for use in women of childbearing potential; systemic absorption is minimal with topical application. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with topical ingenol mebutate. Based on mechanism of action (protein kinase C activator), potential fetal risk cannot be excluded. First trimester: unknown risk; second and third trimesters: unknown risk. Use only if clearly needed and potential benefit justifies potential risk to fetus. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to ingenol mebutate or any component of the formulation."]
| Precautions | ["Severe local skin reactions (e.g., ulceration, blistering, erosion) may occur; use with caution on sun-exposed areas.","Ophthalmic adverse events: Avoid contact with eyes; may cause corneal damage.","Hypersensitivity reactions including anaphylaxis have been reported.","For external use only; not for oral, ophthalmic, or intravaginal administration."] |
Loading safety data…
| Fetal Monitoring | No specific maternal monitoring required beyond usual dermatologic assessment. Fetal monitoring is not indicated unless maternal systemic effects occur (unlikely with topical use). Monitor application site for severe local skin reactions. |
| Fertility Effects | No human data on fertility effects. Animal studies with subcutaneous ingenol mebutate showed no impairment of male or female fertility at doses up to 0.5 mg/kg/day. Topical administration is unlikely to affect fertility due to minimal systemic absorption. |